1-thia-5-aza-bicyclo (4.2.0) Octane Ring Containing (including Dehydrogenated) (e.g., Cephalosporins, Etc.) Patents (Class 514/200)
  • Publication number: 20040096496
    Abstract: Sustained release pharmaceutical compositions comprising at least a cephalosporin antibiotic, a mixture of polymers comprising of galactomannans and neutral swellable polymers, and other pharmaceutically acceptable excipients are described. The composition comprises about 30% to about 90% by weight of a cephalosporin antibiotic; about 1% to about 30% by weight of said mixture of polymers comprising from about 0.1% to about 15% by weight of galactomannans, and about 0.1% to about 15% of neutral swellable polymer by weight of sustained release composition.
    Type: Application
    Filed: August 18, 2003
    Publication date: May 20, 2004
    Applicant: Orchid Chemicals & Pharmaceuticals Limited
    Inventors: Rajesh Suresh Kshirsagar, Sanjay Parbhatrao Boldhane, Kour Chand Jindal
  • Publication number: 20040091455
    Abstract: Methods of treating, preventing and/or managing macular degeneration are disclosed. Specific embodiments encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
    Type: Application
    Filed: October 30, 2003
    Publication date: May 13, 2004
    Inventor: Jerome B. Zeldis
  • Publication number: 20040091454
    Abstract: Methods of treating, preventing and/or managing macular degeneration are disclosed. Specific embodiments encompass the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
    Type: Application
    Filed: October 30, 2003
    Publication date: May 13, 2004
    Inventor: Jerome B. Zeldis
  • Publication number: 20040082560
    Abstract: The present invention provides an improved process for the preparation of cefixime of formula (I), with an improved quality having/possessing better color and solubility.
    Type: Application
    Filed: December 5, 2002
    Publication date: April 29, 2004
    Applicant: ORCHID CHEMICALS AND PHARMACEUTICALS LIMITED
    Inventors: Pandurang Balwant Deshpande, Gautam Kumar Das, Pramod Narayan Deshpande, Ramasubbu Chandrasekaran, Padmanabhan Ramar, John Muthiah Raja Jeyakumar
  • Publication number: 20040072815
    Abstract: Novel antibiotic compositions are described. &bgr;-lactam antibiotics are used in combination with a non-&bgr;-lactam inhibitor of NAALADase, the inhibitor in an amount effective to inhibit &bgr;-lactamase activity. The antibiotic compositions can be administered to treat infections caused by &bgr;-lactamase-producing bacterial strains.
    Type: Application
    Filed: August 5, 2003
    Publication date: April 15, 2004
    Inventor: Gary A. Koppel
  • Publication number: 20040067926
    Abstract: Disclosed is a sustained-release suspension composition containing ceftiofur hydrochloride, tocopherol or a derivative thereof, and a biocompatible oil.
    Type: Application
    Filed: August 4, 2003
    Publication date: April 8, 2004
    Inventors: Yong-Sik Kim, Je Phil Ryoo, Mi-Suk Choi
  • Publication number: 20040062790
    Abstract: The present invention provides methods and compositions involving resorbable hemostatic agents that have the essential absence of microfibrillar collagen. Resorbable hemostatic agents of the present invention comprise polyethylene glycol, which controls bleeding in tissue and does not delay or interfere with healing. The resorbable hemostatic agents of the present invention are biodegradable and biocompatible agents that effectively control bleeding in bone and other tissue without interfering with the subsequent healing of the tissue.
    Type: Application
    Filed: September 26, 2002
    Publication date: April 1, 2004
    Inventors: Barry E. Constantine, Nels J. Lauritzen
  • Publication number: 20040062817
    Abstract: This invention pertains to therapeutic antibacterial/antifungal-wound healing compositions comprise a therapeutically effective amount of antibacterial agents and/or antifungal agents and/or wound healing composition alone. In one embodiment, the wound healing composition comprises (a) zinc oxide and (b) fat-soluble vitamins. The therapeutic antibacterial/antifungal-wound healing compositions may be utilized in a wide variety of pharmaceutical products. This invention also relates to methods for preparing and using the antibacterial/antifungal-wound healing compositions and the pharmaceutical products in which the therapeutic compositions may be used.
    Type: Application
    Filed: September 30, 2003
    Publication date: April 1, 2004
    Inventor: Mickey L. Peshoff
  • Publication number: 20040062757
    Abstract: The invention includes a method of treating gastrointestinal diseases associated with species of genus Clostridium such as clostridium deficit in human patients with gastrointestinal disorders having an etiological component such as a microbial agent producing a toxin where treated with an antimicrobial composition an amount effective to inhibit or eliminate the microbial agent. The antimicrobial composition in a form of probiotic mixture can be administrated alone or in combination with an antimicrobial agent, such as a bacteriophage which is specific for a bacterium producing toxin or antibiotics which are then used to eliminate or inhibit the clostridial species overgrown in a patient's gastrointestinal tract. Disorders that can be treated by the method of the invention include diarrhea or inflammatory bowel diseases such as colitis or Crohn's disease.
    Type: Application
    Filed: October 7, 2003
    Publication date: April 1, 2004
    Inventor: Sydney M. Finegold
  • Patent number: 6709678
    Abstract: An oral composition which is adapted to be dispersed in an aqueous carrier substantially immediately prior to administration comprises a multiplicity of particles comprising an active substance, the particles being combined with one or more gelling or swelling agents capable of forming a viscous medium around the particles in an aqueous carrier as well as being provided with a masking surface layer when dispersed in the aqueous carrier. This serves to mask uneven surfaces on the particles and prevent them from adhering to oral mucosa when the composition is ingested and thus makes it easier to administer large dosages of an active substance. The masking surface layer is preferably provided by an increased viscosity of the viscous medium in the immediate vicinity of the particles relative to the viscosity of the surrounding aqueous carrier. A ready-to-use composition is prepared by mixing the composition with an aqueous carrier substantially immediately prior to administration of the composition.
    Type: Grant
    Filed: February 10, 1999
    Date of Patent: March 23, 2004
    Assignee: Losan Pharma GmbH
    Inventor: Peter Gruber
  • Publication number: 20040052841
    Abstract: The invention describes pharmaceutical preparations with retarding active ingredient release, which consist of mixtures of powdery teicoplanin and at least one powdery, water soluble salt form of gentamicin, clindamycin, kanamycin, amikacin, tobramycin, vancomycin, moxifloxacin and ciprofloxacin and an inorganic and/or organic adjuvant. The pharmaceutical preparations are used as permanent or as temporary implants in the form of tablets, molded bodies, fibers and granules.
    Type: Application
    Filed: June 20, 2003
    Publication date: March 18, 2004
    Applicant: Heraeus Kulzer GmbH & Co.KG
    Inventors: Sebastian Vogt, Matthias Schnabelrauch, Klaus-Dieter Kuhn
  • Publication number: 20040052873
    Abstract: The present invention relates to a bioenhancing/bioavailability-facilitating composition comprising:
    Type: Application
    Filed: March 11, 2003
    Publication date: March 18, 2004
    Applicant: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH
    Inventors: Ghulam Nabi Qazi, Kasturi Lal Bedi, Rakesh Kamal Johri, Manoj Kumar Tickoo, Ashok Kumar Tickoo, Subhash Chander Sharma, Sheikh Tasaduq Abdullah, Om Parkash Suri, Bishan Datt Gupta, Krishan Avtar Suri, Naresh Kumar Satti, Ravi Kant Khajuria, Surjit Singh, Anamika Khajuria, Bal Krishan Kapahi
  • Publication number: 20040033262
    Abstract: This invention relates to a sustained release pharmaceutical composition comprising at least a cephalosporin antibiotic, a mixture of polymers and other pharmaceutically acceptable excipients; in the composition, polymers are selected from mixture of galactomannans and neutral swellable polymers, which releases the active ingredient in a predetermined manner.
    Type: Application
    Filed: August 19, 2002
    Publication date: February 19, 2004
    Applicant: Orchid Health Care
    Inventors: Rajesh Suresh Kshirsagar, Sanjay Parbhatrao Boldhane, Kour Chand Jindal
  • Publication number: 20040033938
    Abstract: A method is provided for treatment of an infective condition in an udder of a milk producing animal. The method comprises intramammary administration of an antibacterial agent in combination therapy with a selective COX-2 inhibitor in therapeutically effective amounts of each. Also provided is a pharmaceutical composition comprising an antibacterial agent and a selective COX-2 inhibitor, together with one or more excipients, in a dosage form suitable for intramammary administration to a milk producing animal.
    Type: Application
    Filed: March 20, 2003
    Publication date: February 19, 2004
    Inventors: Nancy J. Britten, Niki A. Waldron, Jeffrey L. Watts, John W. Hallberg
  • Publication number: 20040029783
    Abstract: A method for treating inhalation anthrax is disclosed. The inventive method comprises the use of 2,3-alkylcarbonyloxybenzoic acid and salts thereof in the prevention and treatment of lung damage caused by Bacillus anthracis and toxins produced by the bacterium. The 2,3-alkylcarbonyloxybenzoic acid may be used alone or in combination with other therapeutic agents such as antibiotics.
    Type: Application
    Filed: October 31, 2002
    Publication date: February 12, 2004
    Inventor: Karen J. Stec
  • Publication number: 20040023897
    Abstract: Methods and pharmaceutical compositions for preventing and treating disease mediated by toxin-secreting bacteria. Inventive methods and compositions are suited to preventing or treating infections caused by bacterial toxins that enter host cells via receptor-mediated endocytosis (e.g., the anthrax and diphtheria toxins). Methods comprise a step of administering to an individual a pharmaceutical composition that includes an effective amount of an inhibitor of endosomal acidification. The inhibitor may be a primary amine, a carboxylic ionophore, or a selective inhibitor of the vacuolar proton pump (V-ATPase). The inhibitors of endosomal acidification may be employed in combination with other therapeutics such as antibiotics and antitoxins in order to prevent, treat or cure the disease.
    Type: Application
    Filed: November 12, 2002
    Publication date: February 5, 2004
    Inventor: Michael J. Caplan
  • Publication number: 20040022848
    Abstract: A pharmaceutical composition containing a drug (A), a waxy substance (B), and synthetic aluminum silicate and/or hydrous silicon dioxide (C). The invention provides a granular pharmaceutical composition suitable for providing a pharmaceutical characterized in that adhesion of granules thereof onto a granulation apparatus during granulation is minimized and caking of the granules is suppressed.
    Type: Application
    Filed: March 17, 2003
    Publication date: February 5, 2004
    Inventors: Hiroshi Kikuchi, Michiko Iketani, Hideo Kobayashi
  • Publication number: 20040022815
    Abstract: The present invention relates to a pharmaceutical oily suspension comprising cephalosporin antibiotic or its pharmaceutically acceptable salt, at least a biocompatible oil, a wetting agent, a dispersing agent and a resuspendibility enhancer, said suspension has improved properties, such as resuspendibility and chemical stability and process thereof.
    Type: Application
    Filed: August 5, 2002
    Publication date: February 5, 2004
    Applicants: ORCHID HEALTH CARE, ANCARE NEW ZEALAND LTD.
    Inventors: Kour Chand Jindal, Majid Razzak, Nilendu Sen
  • Publication number: 20040019011
    Abstract: A combination for administration to a mammal which combination employs a therapeutically effective amount of a medicinal and/or therapeutic agent to treat a disease or condition and an amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and subunits of hyaluronic acid sufficient to facilitate the agent's penetration through the tissue (including scar tissue) at the site to be treated, through the cell membranes into the individual cells to be treated.
    Type: Application
    Filed: July 28, 2003
    Publication date: January 29, 2004
    Inventors: Rudolf Edgar Falk, Samuel S. Asculai
  • Publication number: 20040005361
    Abstract: A pharmaceutical extended-release oral drug delivery system comprising as active ingredient Cefixime Trihydrate in combination with a hydrophilic matrix system, and optionally containing additional pharmaceutically acceptable constituents, wherein at least 20% up to but not more than 40% of Cefixime Trihydrate is released from said matrix within 1 hour from oral administration and the remainder of the pharmaceutical agent is released at a sustained rate.
    Type: Application
    Filed: June 6, 2003
    Publication date: January 8, 2004
    Inventors: Sanjeev Khandelwal, Pratibha Omray
  • Publication number: 20030235615
    Abstract: Antibiotic composition having four dosage forms with different release profiles providing for initial release of a beta lactam antibiotic followed by release of a beta-lactamase inhibitor, followed by release of the antibiotic followed by release of the inhibitor. In a preferred embodiment, release from the second, third and fourth dosage forms is initiated after the component released from the immediately previous form reaches Cmax.
    Type: Application
    Filed: April 21, 2003
    Publication date: December 25, 2003
    Inventor: Edward M. Rudnic
  • Patent number: 6645959
    Abstract: This invention is a method for preventing or treating postoperative ileus comprising administering a vasopressin antagonist such as a compound of Formula (1), where R1, R2, and R3 include hydrogen, halo, alkyl, and alkoxy; R and R5 are hydrogen or alkyl; R4 is hydrogen, phenyl, or substituted phenyl, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: April 19, 2002
    Date of Patent: November 11, 2003
    Assignee: Warner-Lambert Company
    Inventors: Rebecca Guggemos Bakker-Arkema, Milton Lethan Pressler
  • Publication number: 20030206956
    Abstract: The topical application of an azalide antibiotic such as azithromycin to the eye is useful in treating or preventing ocular infections. In one embodiment, the azalide antibiotic is supplied to the eye in a depot for sustained release. A more convenient dosing regimen can also be provided by the use of an appropriate depot. Furthermore, a composition containing a combination of medicaments is also provided.
    Type: Application
    Filed: April 7, 2003
    Publication date: November 6, 2003
    Applicant: INSITE VISION INCORPORATED
    Inventors: Chandler R. Dawson, Lyle M. Bowman
  • Publication number: 20030199432
    Abstract: Co-administration of a lysostaphin or other anti-staphylococcal agent which cleaves cross-links of peptidoglycans of staphylococci cell walls such as lysostaphin and an antibiotic effective against staphylococci due to antibiotic activity mediated by cell-wall activity is effective against staphylococcal infection, even staphylococci that may be resistant to one or other of lysostaphin or the cell-wall active antibiotic. Co-administration simultaneously suppresses the generation of antibiotic-resistant mutant strains. Effective cell-wall active antibiotics include &bgr;-lactams and glycopeptides.
    Type: Application
    Filed: April 16, 2003
    Publication date: October 23, 2003
    Inventors: Michael Climo, Ellen Murphy, Gordon Archer
  • Publication number: 20030191105
    Abstract: A compound of formula 1
    Type: Application
    Filed: December 3, 2002
    Publication date: October 9, 2003
    Inventors: Gerd Ascher, Johannes Ludescher
  • Publication number: 20030191051
    Abstract: The present invention provides compositions and methods for treating or preventing bacterial infections. The compositions and methods include the use of antibiotics and cyclooxygenase inhibitors.
    Type: Application
    Filed: January 21, 2003
    Publication date: October 9, 2003
    Inventors: Philip Needleman, Barry Hafkin
  • Publication number: 20030186339
    Abstract: The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with antibiotic agents.
    Type: Application
    Filed: May 17, 2002
    Publication date: October 2, 2003
    Applicant: McGill University
    Inventor: Brian Leyland-Jones
  • Patent number: 6627625
    Abstract: Administration of &bgr;-lactam compounds including &bgr;-lactam antibiotics and &bgr;-lactamase inhibitors provides significant neurotropic effects in warm-blooded vertebrates evidenced inter alia by anxiolytic and anti-aggressive behavior modification and enhanced cognition. Therapeutic methods for using such compounds and their pharmaceutical formulations are described.
    Type: Grant
    Filed: August 16, 2000
    Date of Patent: September 30, 2003
    Assignee: Revaax Pharmaceuticals, LLC
    Inventor: Gary A. Koppel
  • Publication number: 20030181398
    Abstract: A method of administering an antibiotic to an animal in need thereof, including the step of injecting the antibiotic subcutaneously at the junction of a pinna with the cranium of the animal, is disclosed.
    Type: Application
    Filed: March 19, 2003
    Publication date: September 25, 2003
    Inventor: Scott A. Brown
  • Publication number: 20030171303
    Abstract: The present invention provides a method for synthesizing 1-(acyloxy)-alkyl derivatives from 1-acyl-alkyl derivatives, which typically proceeds stereospecifically, in high yield, does not require the use of activated intermediates and/or toxic compounds and is readily amenable to scale-up. The current invention also provides 1-acyl-alkyl derivatives of known drug compounds and methods for synthesizing these 1-acyl-alkyl derivatives.
    Type: Application
    Filed: June 11, 2002
    Publication date: September 11, 2003
    Inventors: Mark A. Gallop, Jia-Ning Xiang, Fenmei Yao, Laxminarayan Bhat, Cindy X. Zhou
  • Publication number: 20030170307
    Abstract: This invention relates generally to the production and use of inorganic-polymer complexes for the controlled release of compounds including medicinals. Advantageously, the inorganic used is calcium sulfate.
    Type: Application
    Filed: February 13, 2003
    Publication date: September 11, 2003
    Applicant: Royer Biomedical, Inc.
    Inventor: Garfield P. Royer
  • Publication number: 20030170326
    Abstract: The present invention relates to a bio enhancing composition containing extract and/or bioactive fraction/isolate from the plant Zingiber officinale in combinations combination with drugs, nutrients, nutraceuticals, micronutrients and herbal drugs/products and optionally containing piperine as a extract/active fraction obtained from piper nigrum, piper longum or its oleoresin as a bioavailability enhancer and its process for producing the extract or fractions from the plant source.
    Type: Application
    Filed: December 12, 2002
    Publication date: September 11, 2003
    Applicant: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH
    Inventors: Ghulam Nabi Qazi, Kasturi Lal Bedi, Rakesh Kamal Johri, Manoj Kumar Tikoo, Ashok Kumar Tikoo, Subhash Chander Sharma, Sheikh Tasaduq Abdullah, Om Parkash Suri, Bishan Datt Gupta, Krishan Avtar Suri, Naresh Kumar Satti, Ravi Kant Khajuria, Surjeet Singh, Anamika Khajuria, Bal Krishan Kapahi
  • Publication number: 20030161888
    Abstract: A composition comprising cefuroxime axetil in particulate form, the particles being coated with integral coatings of a lipid or mixture of lipids which are insoluble in water in which the composition further comprises a sweetener system and a texture modifier which serves to mask the bitter taste of cefuroxime axetil upon oral administration is disclosed.
    Type: Application
    Filed: November 21, 2002
    Publication date: August 28, 2003
    Inventors: Matilde Ibanez Fernandez, Emilio Sanz Garriz
  • Publication number: 20030162695
    Abstract: Glucocorticoid blockers, including glucocorticoid receptor antagonists, are effective to prevent glucocorticoid-induced decrease in permeability of the blood-brain barrier and to increase the permeability of the blood-brain barrier. Administration of glucocorticoid blockers, including glucocorticoid receptor antagonists, concomitant with administration of drugs for treating diseases of the central nervous system increases delivery of such drugs into the central nervous system.
    Type: Application
    Filed: February 27, 2002
    Publication date: August 28, 2003
    Inventors: Alan F. Schatzberg, Steven Lindley, Joseph K. Belanoff
  • Publication number: 20030147960
    Abstract: This invention relates to an ionic antimicrobial coating. Such a coating may contain (1) a water-insoluble polymer having a first ionized group and (2) an antimicrobial agent having a second ionized group with a charge opposite to that of the first ionized group, in which the antimicrobial agent is attached to the water-insoluble polymer via an ionic bond between the first ionized group and the second ionized group.
    Type: Application
    Filed: February 21, 2003
    Publication date: August 7, 2003
    Inventors: Tung-Liang Lin, Min-Shyan Sheu
  • Publication number: 20030143293
    Abstract: This invention relates to compositions, methods, combinations, and kits for treating, preventing, or reducing the risk of developing diarrhea in a mammal; or treating, preventing, or reducing the risk of developing a symptom associated with, or related to, diarrhea in a mammal. In particular, the compositions, methods, combinations, and kits comprise an anti-diarrheal agent and an electrolyte.
    Type: Application
    Filed: January 31, 2002
    Publication date: July 31, 2003
    Inventor: Sergei Shushunov
  • Patent number: 6599892
    Abstract: Derivatives of 7-alkylidene cephalosporanic acid sulfone and the pharmaceutically active salts thereof are found to be potent inhibitors of &bgr;-lactamase enzymes.
    Type: Grant
    Filed: July 30, 2001
    Date of Patent: July 29, 2003
    Assignee: Research Corporation Technologies, Inc.
    Inventors: John D. Buynak, Brian Bachmann
  • Publication number: 20030139382
    Abstract: Aqueous suspension formulations containing dexamethasone and ciprofloxacin are disclosed for the treatment of middle ear infections in human patients having an open tympanic membrane.
    Type: Application
    Filed: September 13, 2002
    Publication date: July 24, 2003
    Applicant: Alcon, Inc.
    Inventors: G. Michael Wall, Peter J. Conroy
  • Publication number: 20030134779
    Abstract: The present invention relates to a new composition, use and method to improve the cure of infections caused by antibiotic resistant microbial pathogens, in particular beta-lactam resistant microorganisms. Lactoferrin (LF) or Lactoferricin (LFC) can be administrated alone or in combination with antibiotic to affect growth, physiology and morphology of targeted microorganism. Lactoferrin increase susceptibility and can reverse resistance of microorganism to antibiotics.
    Type: Application
    Filed: September 23, 2002
    Publication date: July 17, 2003
    Inventors: Moussa S. Diarra, Pierre Lacasse, Denis Petitclerc
  • Publication number: 20030129227
    Abstract: This invention provides &bgr;-lactam antibiotic-containing tablets capable of being orally taken either as such owing to their being small-sized, hence still easily swallowable, or, in the case of administration to the aged encountering some difficulty in swallowing, in the form of dispersions resulting from easy self-disintegration upon being dropped into water in a glass as well as a method of producing the same. The tablets of this invention comprise, on the per-tablet basis, 60-85% by weight of a &bgr;-lactam antibiotic, 1-10% by weight of low-substituted hydroxypropylcellulose and/or crosslinked polyvinylpyrrolidone as a disintegrator, and 0.5-2% by weight of a binder. Granules to be compressed for tableting are prepared using water or an aqueous solution of ethanol or the like.
    Type: Application
    Filed: January 17, 2003
    Publication date: July 10, 2003
    Applicant: Fujisawa Pharmaceutical Co. Ltd.
    Inventor: Hisami Yamaguchi
  • Publication number: 20030130171
    Abstract: The present invention relates to microbial multidrug resistance and, in particular, to compounds that microbial drug transporters of the ABC protein superfamily. The invention also relates to methods for selecting or designing compounds for the ability to inhibit drug transporter proteins and to methods of inhibiting drug transporter proteins. The invention concerns the new use of opioid receptor antagonists in the treatment of multidrug resistant microbial infections.
    Type: Application
    Filed: October 30, 2001
    Publication date: July 10, 2003
    Inventor: Grant L. Schoenhard
  • Publication number: 20030124644
    Abstract: Methods are provided for increasing and altering the timing of antibiotic production in Streptomyces species, particularly S. coelicolor and S. lividans, by functionally deleting the S. coelicolor scbA and scbR genes, respectively, or their homologues. Also provided are strains having such mutations, and methods of producing antibiotics using such strains. Also provided are methods for identifying strains in which functional deletion of the scbA and/or scbR genes or their homologues leads to the above effects.
    Type: Application
    Filed: October 23, 2001
    Publication date: July 3, 2003
    Inventors: Eriko Takano, Mervyn J. Bibb
  • Publication number: 20030124597
    Abstract: A nucleic acid sequence which regulates the autolytic activity of bacteria is provided. Methods for identifying and using agents which interact with the gene to inhibit bacterial growth and infectivity also are provided.
    Type: Application
    Filed: November 6, 2002
    Publication date: July 3, 2003
    Inventor: Ambrose Cheung
  • Publication number: 20030124141
    Abstract: The invention provides Helicobacter polypeptides that can be used in vaccination methods for preventing or treating Helicobacter infection, and polynucleotides that encode these polypeptides.
    Type: Application
    Filed: November 16, 2001
    Publication date: July 3, 2003
    Inventors: Rainer Haas, Harold Kleanthous, Jean-Francois Tomb, Charles Miller, Amal Al-Garawi, Stefan Odenbreit, Thomas Meyer
  • Publication number: 20030118654
    Abstract: A substantially taste masked liquid pharmaceutical composition containing a pharmaceutically effective amount of an unpleasant tasting drug dissolved or dispersed in an aqueous excipient base, said excipient base comprising polyvinyl pyrrolidone and/or copolyvidone, and high molecular weight polyethylene glycol.
    Type: Application
    Filed: December 7, 2001
    Publication date: June 26, 2003
    Inventors: Joyce Bedelia B. Santos, Rita Josefina M. Santos, Kennie U. Dee
  • Patent number: 6583133
    Abstract: Disclosed are cephalosporin derivatives of the general formula wherein R is an organic residue with a molecular weight not exceeding 400 bonded to the adjacent sulphur atom via carbon and consisting of carbon, hydrogen, and optional oxygen, sulfur, nitrogen and/or halogen atoms; R1 is hydrogen, lower alkyl or phenyl; and A is a secondary, tertiary or quaternary nitrogen atom bound directly to the propenyl group and being substituted by an organic residue with a molecular weight not exceeding 400 and consisting of carbon, hydrogen, and optional oxygen, sulfur, nitrogen and/or halogen atoms, as well as readily hydrolyzable esters thereof, pharmaceutically acceptable salts of said compounds and hydrates of the compounds of formula I and of their esters and salts.
    Type: Grant
    Filed: June 22, 1999
    Date of Patent: June 24, 2003
    Assignee: Basilea Pharmaceutica AG
    Inventors: Peter Angehrn, Erwin Götschi, Ingrid Heinze-Krauss, Hans G. F. Richter
  • Publication number: 20030113385
    Abstract: Certain extracts of plants from the genera Leptospernum and Melaleuca can be used in the treatment of both mastitis and metritis to effectively reduce the amount of antibiotic employed, which extracts contain terpene.
    Type: Application
    Filed: August 15, 2002
    Publication date: June 19, 2003
    Applicant: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Werner Schleicher, Ernst Salamon
  • Publication number: 20030109503
    Abstract: A method of use of clavulanate to enhance the antibacterial activity of an antibacterial compound against microorganisms having an antibiotic resistance mechanism other than &bgr;-lactans enzyme mediated resistance. Pharmaceutical formulations and methods of use which exploit this method.
    Type: Application
    Filed: December 17, 2002
    Publication date: June 12, 2003
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Gillian Marjory Smith, Christine Elaine Thorburn, Karen Hazel Abbott, Tim Neil Brown
  • Publication number: 20030105066
    Abstract: Nitrate salts of antimicrobial agents for the preparation of antimicrobial medicaments, specifically antiviral, antifungal and antibacterial medicaments.
    Type: Application
    Filed: July 24, 2002
    Publication date: June 5, 2003
    Inventors: Piero Del Soldato, Francesca Benedini
  • Publication number: 20030100002
    Abstract: A nucleic acid sequence which regulates the autolytic activity of bacteria is provided. Also provided are polypeptides encoded by these nucleic acid sequences or mutants thereof as well as vector and host cells for expressing these polypeptides. Methods for identifying and using agents which prevent or reduce multiple antibiotic resistance also are provided.
    Type: Application
    Filed: November 6, 2002
    Publication date: May 29, 2003
    Inventor: Ambrose Cheung